A New Approach to Disease Treatment
A New Model for Drug Discovery
Small-molecule drug development remains slow, costly, and uncertain. Traditional “one drug, one target, hit hard” strategies can face resistance, dose-limiting toxicity, and short-lived responses.
Parkside Scientific takes a systems-level approach to epigenetic drug discovery. We aim to reset disease-driving gene-expression networks by modulating their regulatory machinery.
Rethinking the Root of Disease
Gene expression governs cell behavior in response to signals. Mutations and abnormal signaling may start disease. Disease progression often involves disruption of epigenetic and transcriptional programs across cell types.
Bromodomain (BrD) proteins recognize acetylated lysines on histones and other proteins to regulate gene expression. When dysregulated, they can sustain gene programs driving cancer and chronic inflammation.
Parkside’s Breakthrough
First-generation BET inhibitors, including pelabresib1, target BET-family bromodomain proteins. Dose-limiting toxicity and short-lived responses can limit their benefit, especially as single agents.
Parkside’s proprietary STAMP™ platform2 modulates multiple acetylation-dependent transcription and chromatin regulators. It aims to widen the therapeutic window and yield deeper, durable responses.
PS1132 is an oral STAMP™ BrD inhibitor. Preclinical studies showed stronger tumor regression than pelabresib and a fivefold wider therapeutic index, with suppression of c-MYC, BCL2, and CDK6. It showed high oral exposure and was well tolerated in 28-day GLP toxicology studies. A small Phase 1a pilot trial provided favorable exposure, safety, and pharmacokinetic data over pelabresib, with early activity signals in refractory T- and B-cell non-Hodgkin lymphomas (NHL). Patients’ disease had resisted chemotherapy, immunotherapy, and targeted agents, including JAK1, PI3Kδ, and BTK inhibitors. These findings support further clinical study and a distinct co-development opportunity.
A Platform with Broad Potential
The STAMP™ platform has potential across diseases driven by abnormal gene-expression programs. Beyond hematologic cancers, our pipeline spans solid tumors, including prostate and breast cancer, and chronic inflammatory and neurodegenerative diseases, including inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, and Alzheimer’s disease.
Partner with Parkside
Parkside is developing next-generation epigenetic medicines to reset disease-driving gene programs, aiming for safer, durable therapies. We seek partners with development skills and funding. Together, we can advance programs through agreed milestones.
To discuss investment and co-development opportunities, contact info@pksci.com.
10/2026
[1] At JPM 2026, Novartis announced a planned EMA filing for pelabresib plus ruxolitinib in myelofibrosis and an FDA-agreed Phase 3 path. [2] STAMP™—Single Therapeutic Acts on Multiple Proteins.